MannKind shares rose 3.7% after earnings, as investors may have welcomed rapid Furoscix ReadyFlow conversion and accelerating Afrezza prescriptions. The company also reported 27% year-to-date revenue growth, though its outlook leans on a record fourth quarter to reach profitability.
- Revenue for the first nine months was $301 million, up 27% year over year. Afrezza and Furoscix revenue more than doubled to $112 million; royalties rose 8% to $103 million.
- By late October, about 75% of Furoscix shipments had shifted to ReadyFlow, ahead of management’s internal expectations. The company expects Q4 Furoscix sales to match the entire first half of 2027.
- Afrezza average monthly new-to-brand prescriptions increased nearly 80% in Q3 versus Q2, and management said the pediatric launch exceeded internal forecasts.
- MannKind expects record Q4 revenue to bring it to profitability by year-end. It also anticipates $15 million in ralinepag DPI milestones in 2027.
- Nintedanib DPI’s Phase Ib results showed safety and tolerability, particularly regarding cough; the company expects a Phase II data readout in the first half of 2028.
Community Discussion